Affordable drug resistance genotyping of HIV-1 reverse transcriptase, protease and integrase genes, for resource limited settings. 2023

Sontaga Manyana, and Melendhran Pillay, and Lilishia Gounder, and Aabida Khan, and Pravi Moodley, and Kogieleum Naidoo, and Benjamin Chimukangara
Department of Virology, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal and National Health Laboratory Service, 800 Vusi Mzimela Road, Durban, 4058, South Africa.

As use of dolutegravir (DTG) becomes more common in resource limited settings (RLS), the demand for integrase resistance testing is increasing. Affordable methods for genotyping all relevant HIV-1 pol genes (i.e., protease (PR), reverse transcriptase (RT) and integrase (IN)) are required to guide choice of future antiretroviral therapy (ART). We designed an in-house HIV-1 drug resistance (HIVDR) genotyping method that is affordable and suitable for use in RLS. We obtained remnant plasma samples from CAPRISA 103 study and amplified HIV-1 PR, RT and IN genes, using an innovative PCR assay. We validated the assay using remnant plasma samples from an external quality assessment (EQA) programme. We genotyped samples by Sanger sequencing and assessed HIVDR mutations using the Stanford HIV drug resistance database. We compared drug resistance mutations with previous genotypes and calculated method cost-estimates. From 96 samples processed, we obtained sequence data for 78 (81%), of which 75 (96%) had a least one HIVDR mutation, with no major-IN mutations observed. Only one sample had an E157Q INSTI-accessory mutation. When compared to previous genotypes, 18/78 (23%) had at least one discordant mutation, but only 2/78 (3%) resulted in different phenotypic predictions that could affect choice of subsequent regimen. All CAPRISA 103 study sequences were HIV-1C as confirmed by phylogenetic analysis. Of the 7 EQA samples, 4 were HIV-1C, 2 were HIV-1D, and 1 was HIV-1A. Genotypic resistance data generated using the IDR method were 100% concordant with EQA panel results. Overall genotyping cost per sample was estimated at ~ US$43-$US49, with a processing time of ~ 2 working days. We successfully designed an in-house HIVDR method that is suitable for genotyping HIV-1 PR, RT and IN genes, at an affordable cost and shorter turnaround time. This HIVDR genotyping method accommodates changes in ART regimens and will help to guide HIV-1 treatment decisions in RLS.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D010447 Peptide Hydrolases Hydrolases that specifically cleave the peptide bonds found in PROTEINS and PEPTIDES. Examples of sub-subclasses for this group include EXOPEPTIDASES and ENDOPEPTIDASES. Peptidase,Peptidases,Peptide Hydrolase,Protease,Proteases,Proteinase,Proteinases,Proteolytic Enzyme,Proteolytic Enzymes,Esteroproteases,Enzyme, Proteolytic,Hydrolase, Peptide
D010802 Phylogeny The relationships of groups of organisms as reflected by their genetic makeup. Community Phylogenetics,Molecular Phylogenetics,Phylogenetic Analyses,Phylogenetic Analysis,Phylogenetic Clustering,Phylogenetic Comparative Analysis,Phylogenetic Comparative Methods,Phylogenetic Distance,Phylogenetic Generalized Least Squares,Phylogenetic Groups,Phylogenetic Incongruence,Phylogenetic Inference,Phylogenetic Networks,Phylogenetic Reconstruction,Phylogenetic Relatedness,Phylogenetic Relationships,Phylogenetic Signal,Phylogenetic Structure,Phylogenetic Tree,Phylogenetic Trees,Phylogenomics,Analyse, Phylogenetic,Analysis, Phylogenetic,Analysis, Phylogenetic Comparative,Clustering, Phylogenetic,Community Phylogenetic,Comparative Analysis, Phylogenetic,Comparative Method, Phylogenetic,Distance, Phylogenetic,Group, Phylogenetic,Incongruence, Phylogenetic,Inference, Phylogenetic,Method, Phylogenetic Comparative,Molecular Phylogenetic,Network, Phylogenetic,Phylogenetic Analyse,Phylogenetic Clusterings,Phylogenetic Comparative Analyses,Phylogenetic Comparative Method,Phylogenetic Distances,Phylogenetic Group,Phylogenetic Incongruences,Phylogenetic Inferences,Phylogenetic Network,Phylogenetic Reconstructions,Phylogenetic Relatednesses,Phylogenetic Relationship,Phylogenetic Signals,Phylogenetic Structures,Phylogenetic, Community,Phylogenetic, Molecular,Phylogenies,Phylogenomic,Reconstruction, Phylogenetic,Relatedness, Phylogenetic,Relationship, Phylogenetic,Signal, Phylogenetic,Structure, Phylogenetic,Tree, Phylogenetic
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006679 HIV Seropositivity Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV). AIDS Seroconversion,AIDS Seropositivity,Anti-HIV Positivity,HIV Antibody Positivity,HIV Seroconversion,HTLV-III Seroconversion,HTLV-III Seropositivity,AIDS Seroconversions,AIDS Seropositivities,Anti HIV Positivity,Anti-HIV Positivities,Antibody Positivities, HIV,Antibody Positivity, HIV,HIV Antibody Positivities,HIV Seroconversions,HIV Seropositivities,HTLV III Seroconversion,HTLV III Seropositivity,HTLV-III Seroconversions,HTLV-III Seropositivities,Positivities, Anti-HIV,Positivities, HIV Antibody,Positivity, Anti-HIV,Positivity, HIV Antibody,Seroconversion, AIDS,Seroconversion, HIV,Seroconversion, HTLV-III,Seroconversions, AIDS,Seroconversions, HIV,Seroconversions, HTLV-III,Seropositivities, AIDS,Seropositivities, HIV,Seropositivities, HTLV-III,Seropositivity, AIDS,Seropositivity, HIV,Seropositivity, HTLV-III
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000092943 Resource-Limited Settings Environments with barriers to quality critical care characterized by lack of epidemiological data and context-specific evidence for medical decision-making, deficiencies in health systems organization and resources, and institutional obstacles to implementation of life-saving interventions. Austere Conditions,Austere Environment,Low Resource Settings,Resource Limited Areas,Resource Limited Regions,Area, Resource Limited,Areas, Resource Limited,Austere Condition,Austere Environments,Condition, Austere,Conditions, Austere,Environment, Austere,Environments, Austere,Limited Area, Resource,Limited Areas, Resource,Limited Region, Resource,Limited Regions, Resource,Low Resource Setting,Region, Resource Limited,Regions, Resource Limited,Resource Limited Area,Resource Limited Region,Resource Limited Settings,Resource Setting, Low,Resource Settings, Low,Resource-Limited Setting,Setting, Low Resource,Setting, Resource-Limited,Settings, Low Resource,Settings, Resource-Limited
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D019426 Integrases Recombinases that insert exogenous DNA into the host genome. Examples include proteins encoded by the POL GENE of RETROVIRIDAE and also by temperate BACTERIOPHAGES, the best known being BACTERIOPHAGE LAMBDA. Integrase
D019427 HIV Integrase Enzyme of the HUMAN IMMUNODEFICIENCY VIRUS that is required to integrate viral DNA into cellular DNA in the nucleus of a host cell. HIV integrase is a DNA nucleotidyltransferase encoded by the pol gene. HIV Integration Protein,p31 Integrase Protein, HIV,p31 Integrase Protein, Human Immunodeficiency Virus,p31 pol Gene Product, HIV,p31 pol Gene Product, Human Immunodeficiency Virus,Integrase, HIV,Integration Protein, HIV

Related Publications

Sontaga Manyana, and Melendhran Pillay, and Lilishia Gounder, and Aabida Khan, and Pravi Moodley, and Kogieleum Naidoo, and Benjamin Chimukangara
March 2014, Journal of visualized experiments : JoVE,
Sontaga Manyana, and Melendhran Pillay, and Lilishia Gounder, and Aabida Khan, and Pravi Moodley, and Kogieleum Naidoo, and Benjamin Chimukangara
January 2013, Methods in molecular biology (Clifton, N.J.),
Sontaga Manyana, and Melendhran Pillay, and Lilishia Gounder, and Aabida Khan, and Pravi Moodley, and Kogieleum Naidoo, and Benjamin Chimukangara
July 2016, Journal of virology,
Sontaga Manyana, and Melendhran Pillay, and Lilishia Gounder, and Aabida Khan, and Pravi Moodley, and Kogieleum Naidoo, and Benjamin Chimukangara
December 2014, Retrovirology,
Sontaga Manyana, and Melendhran Pillay, and Lilishia Gounder, and Aabida Khan, and Pravi Moodley, and Kogieleum Naidoo, and Benjamin Chimukangara
January 2007, AIDS (London, England),
Sontaga Manyana, and Melendhran Pillay, and Lilishia Gounder, and Aabida Khan, and Pravi Moodley, and Kogieleum Naidoo, and Benjamin Chimukangara
June 2018, AIDS research and human retroviruses,
Sontaga Manyana, and Melendhran Pillay, and Lilishia Gounder, and Aabida Khan, and Pravi Moodley, and Kogieleum Naidoo, and Benjamin Chimukangara
January 2019, F1000Research,
Sontaga Manyana, and Melendhran Pillay, and Lilishia Gounder, and Aabida Khan, and Pravi Moodley, and Kogieleum Naidoo, and Benjamin Chimukangara
June 2013, Journal of clinical microbiology,
Sontaga Manyana, and Melendhran Pillay, and Lilishia Gounder, and Aabida Khan, and Pravi Moodley, and Kogieleum Naidoo, and Benjamin Chimukangara
August 1998, AIDS (London, England),
Sontaga Manyana, and Melendhran Pillay, and Lilishia Gounder, and Aabida Khan, and Pravi Moodley, and Kogieleum Naidoo, and Benjamin Chimukangara
December 2010, Mini reviews in medicinal chemistry,
Copied contents to your clipboard!